A first-in-human trial of PRT12396 starts next month.
ApexOnco Front Page
Recent articles
Early data are coming with the KRAS G12D degrader ARV-806.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
After Aktis's $318m flotation Eikon is a bigger proposition.
The company secures funding to push its lead candidate towards US approval.
Prexasertib data worsen again, and biomarkers are up in the air.
Readout of the Pivot-006 trial is brought forward by nearly a year.
$650m buys the group rights to RemeGen’s RC148.
